Laquinimod
- Generic Name
- Laquinimod
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H17ClN2O3
- CAS Number
- 248281-84-7
- Unique Ingredient Identifier
- 908SY76S4G
- Background
Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries. It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. It has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally.
- Indication
Investigated for use/treatment in multiple sclerosis.
- Associated Conditions
- -
- Associated Therapies
- -
An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease
- Conditions
- Interventions
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Teva Pharmaceutical Industries, Ltd.
- Target Recruit Count
- 257
- Registration Number
- NCT00745615
- Locations
- 🇩🇪
Teva Investigational Site 681, Berlin, Germany
🇷🇺Teva Investigational Site 185, St. Petersburg, Russian Federation
ðŸ‡ðŸ‡ºTeva Investigational Site 581, Gyula, Hungary
Laquinimod Phase IIa Study in Active Crohn's Disease
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2015-03-20
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT00737932
- Locations
- 🇫🇷
Teva Investigational Site 5354, Nice, France
🇫🇷Teva Investigational Site 5355, Paris, France
🇧🇪Teva Investigational Site 3711, Bonheiden, Belgium
BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
- Conditions
- Interventions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1331
- Registration Number
- NCT00605215
- Locations
- 🇺🇸
Teva Investigational Site 1263, Shreveport, Louisiana, United States
🇷🇴Teva Investigational Site 5219, Sibiu, Romania
🇩🇪Teva Investigational Site 6402, Berlin, Germany
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1106
- Registration Number
- NCT00509145
- Locations
- 🇵🇱
Teva Investigational Site 5320, Gorzow Wielkopolski, Poland
🇷🇺Teva Investigational Site 5026, Saint-Petersburg, Russian Federation
🇷🇺Teva Investigational Site 5023, St. Petersburg, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.